50 - Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Liana Nikolaenko,Lu Chen,Alex F Herrera,Lihua E Budde,Matthew Mei,Tanya Siddiqi,Robert Chen,Jasmine Zain,Larry W Kwak,Steven Rosen,Leslie Popplewell

doi:10.1016/s2666-6367(21)00076-2

50 - Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Liana Nikolaenko, Lu Chen + Show 9 more

Open Access

https://doi.org/10.1016/s2666-6367(21)00076-2

Copy DOI

Journal: Biology of Blood and Marrow Transplantation	Publication Date: Jan 31, 2021
License type: cc-by-nc-nd

#Rituximab, Ifosfamide, Carboplatin, Etoposide #Second-Line Therapy For Patients + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

50 - Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Full Text